Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.

@article{Li2006BiotransformationOC,
  title={Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.},
  author={Wenying Li and Donglu Zhang and Lifei Wang and Hao H. Zhang and Peter T. W. Cheng and Duxi Zhang and Donald W. Everett and W Griffith Humphreys},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2006},
  volume={34 5},
  pages={807-20}
}
Muraglitazar (Pargluva; Bristol-Myers Squibb), a dual alpha/gamma peroxisome proliferator-activated receptor activator, is under development for treatment of type 2 diabetes. This study describes the biotransformation profile of carbon-14-labeled muraglitazar in plasma, urine, feces, and bile samples from male CD-1 mice [intact and bile duct cannulation (BDC)] after single oral doses of 1 and 40 mg/kg. The major drug-related component circulating in mouse plasma was the parent compound for up… CONTINUE READING